ALDX — Aldeyra Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1341235 ·
Last close
$1.78
Market Cap
$107.37M
52W High
$5.74
52W Low
$1.07
ADV30
1,085,715
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,546,918 | -3,452,619 | 66,483,081 | 65,002,305 | 24,326,289 |
| Dec 2025 | 0 | — | -6,667,883 | -6,461,507 | 72,059,317 | 70,041,254 | 27,808,927 |
| Sep 2025 | 0 | — | -8,001,132 | -7,688,341 | 77,801,012 | 59,340,599 | 28,556,469 |
| Jun 2025 | 0 | — | -10,168,732 | -9,767,312 | 84,962,888 | 41,241,269 | 29,674,746 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-33,345,682
Investing CF
$47,736,288
Financing CF
$1,123,556
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.71
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-483,957,253
Inventory
—
Receivables
$755,545
ST Investments
$0
EBIT TTM
$-31,941,352
Pretax Income TTM
$-33,846,661
Interest Exp TTM
$1,905,309
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -35,265,206 | -33,846,661 | 72,059,317 | 27,808,927 | — | -33,345,682 |
| Dec 2024 | 0 | -60,117,032 | -55,851,444 | 104,606,694 | 33,601,823 | — | -43,208,747 |
| Dec 2023 | 0 | -42,794,083 | -37,542,510 | 148,326,911 | 28,531,881 | — | -30,326,128 |
| Dec 2022 | 0 | -62,679,987 | -62,024,636 | 181,291,657 | 30,283,628 | — | -56,637,187 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PEPG | PepGen Inc. | $105.83M | $1.53 | — |
| COYA | Coya Therapeutics, Inc. | $110.48M | $4.71 | — |
| INO | INOVIO PHARMACEUTICALS, INC. | $103.66M | $1.26 | — |
| VRCA | Verrica Pharmaceuticals Inc. | $103.42M | $6.02 | — |
| PYXS | Pyxis Oncology, Inc. | $103.27M | $1.63 | — |
News headlines (Yahoo Finance, 1h cache)
Upstart Holdings Leads These 3 Stocks Estimated To Be Trading Below Fair Value
2026-05-15 17:38 · Yahoo
3 Stocks That May Be Undervalued According To Analysts In May 2026
2026-05-15 11:37 · Yahoo
Pleasing Signs As A Number Of Insiders Buy Aldeyra Therapeutics Stock
2026-05-05 10:55 · Yahoo
Extreme Networks And 2 Additional Stocks Estimated To Be Trading Below Their Fair Value
2026-05-01 17:38 · Yahoo
Discover 3 Stocks That Might Be Trading Below Estimated Value
2026-05-01 11:38 · Yahoo
3 Stocks Estimated To Be Trading Below Intrinsic Value By Up To 35.4%
2026-04-29 17:38 · Yahoo
3 Stocks That May Be Trading Below Their Estimated Value In April 2026
2026-04-29 11:38 · Yahoo
April 2026's Top 3 Stocks That May Be Trading Below Estimated Fair Value
2026-04-27 17:38 · Yahoo
3 Stocks That Might Be Undervalued By Up To 32.8%
2026-04-27 11:38 · Yahoo
3 Stocks That May Be Undervalued By Up To 48.1% According To Intrinsic Value Estimates
2026-04-10 17:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.